Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Assets (2023 - 2025)

Zhengye Biotechnology Holding has reported Assets over the past 3 years, most recently at $61.5 million for Q4 2025.

  • Quarterly Assets fell 10.38% to $61.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.5 million through Dec 2025, down 10.38% year-over-year, with the annual reading at $62.4 million for FY2025, 7.64% down from the prior year.
  • Assets was $61.5 million for Q4 2025 at Zhengye Biotechnology Holding, down from $70.4 million in the prior quarter.
  • Over five years, Assets peaked at $70.4 million in Q2 2025 and troughed at $61.5 million in Q4 2025.
  • The 3-year median for Assets is $69.0 million (2024), against an average of $67.5 million.
  • Year-over-year, Assets decreased 1.1% in 2024 and then dropped 10.38% in 2025.
  • A 3-year view of Assets shows it stood at $69.4 million in 2023, then decreased by 1.1% to $68.7 million in 2024, then decreased by 10.38% to $61.5 million in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Assets are $61.5 million (Q4 2025), $70.4 million (Q2 2025), and $68.7 million (Q4 2024).